Suraksha Diagnostic Ltd. (IN:SURAKSHA)
:SURAKSHA
Want to see IN:SURAKSHA full AI Analyst Report?
Top Page
Suraksha Diagnostic Ltd.
(SURAKSHA)
Select Model
Select Model
Rating:62Neutral
Price Target:
₹277.00
▼(-7.93% Downside)
Action:ReiteratedDate:10/18/25
Suraksha Diagnostic Ltd. demonstrates strong financial performance, which is the most significant factor in its overall score. However, the stock's technical indicators suggest potential bearish momentum, and its high P/E ratio indicates overvaluation, which negatively impacts the overall score.
Positive Factors
High profitability margins
Sustained high gross and healthy net margins indicate durable pricing power and efficient laboratory operations. Such margins support reinvestment in capacity and technology, provide a cushion against reimbursement pressure, and improve long-term free cash flow potential.
Negative Factors
Rising liabilities trend
A gradual rise in total liabilities, despite moderate leverage today, raises medium-term risk if growth requires additional funding or if interest costs increase. Persistent liability growth could limit flexibility for capex or acquisitions and elevate refinancing risk.
Read all positive and negative factors
Positive Factors
Negative Factors
High profitability margins
Sustained high gross and healthy net margins indicate durable pricing power and efficient laboratory operations. Such margins support reinvestment in capacity and technology, provide a cushion against reimbursement pressure, and improve long-term free cash flow potential.
Read all positive factors
Suraksha Diagnostic Ltd. (SURAKSHA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹14.69B
Dividend YieldN/A
Average Volume (3M)1.23K
Price to Earnings (P/E)46.7
Beta (1Y)1.21
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees1,175
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)1.60
Shares Outstanding52,080,757
10 Day Avg. Volume1,073
30 Day Avg. Volume1,225
Financial Highlights & Ratios
PEG Ratio1.29
Price to Book (P/B)6.74
Price to Sales (P/S)5.65
P/FCF Ratio66.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)7.15
Revenue Forecast (FY)₹3.49B
Suraksha Diagnostic Ltd. Business Overview & Revenue Model
Company Description
Established in 1992 as Suraksha Diagnostics & Eye Centre (P) Ltd. in Kolkata, they started as one of the first diagnostic centers in Kolkata to provide all pathology and radiology services under one roof. This convenience, along with their unwaver...
How the Company Makes Money
Suraksha Diagnostic Ltd. primarily makes money by charging fees for diagnostic services delivered to patients and referred by healthcare providers. Its core revenue streams typically include: (1) Pathology/laboratory testing revenue—income from ro...
Suraksha Diagnostic Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
75
Positive
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.76B | 2.52B | 2.19B | 1.90B | 2.23B | 1.40B |
| Gross Profit | 1.81B | 2.23B | 1.91B | 762.56M | 862.85M | 1.07B |
| EBITDA | 884.82M | 850.88M | 728.39M | 474.79M | 652.53M | 238.14M |
| Net Income | 319.26M | 318.24M | 236.26M | 65.16M | 208.24M | 64.35M |
Balance Sheet | ||||||
| Total Assets | 3.80B | 3.34B | 3.00B | 2.81B | 2.76B | 1.71B |
| Cash, Cash Equivalents and Short-Term Investments | 435.94M | 226.36M | 515.96M | 522.79M | 412.89M | 98.42M |
| Total Debt | 1.18B | 888.86M | 904.76M | 968.74M | 997.95M | 164.31M |
| Total Liabilities | 1.51B | 1.23B | 1.21B | 1.26B | 1.30B | 448.24M |
| Stockholders Equity | 2.30B | 2.11B | 1.79B | 1.56B | 1.46B | 1.26B |
Cash Flow | ||||||
| Free Cash Flow | 132.32M | 213.35M | 157.90M | 309.29M | 385.74M | 81.11M |
| Operating Cash Flow | 366.93M | 633.59M | 604.84M | 440.96M | 578.23M | 235.12M |
| Investing Cash Flow | -218.05M | -395.84M | -349.96M | -207.95M | -432.81M | -277.08M |
| Financing Cash Flow | -150.27M | -240.48M | -251.30M | -243.28M | -142.85M | 32.11M |
Suraksha Diagnostic Ltd. Technical Analysis
Positive
300.85
Price Trends
268.10
Positive
272.18
Positive
291.18
Negative
Market Momentum
4.26
Negative
64.35
Neutral
82.92
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SURAKSHA, the sentiment is Positive. The current price of 300.85 is above the 20-day moving average (MA) of 258.26, above the 50-day MA of 268.10, and above the 200-day MA of 291.18, indicating a neutral trend. The MACD of 4.26 indicates Negative momentum. The RSI at 64.35 is Neutral, neither overbought nor oversold. The STOCH value of 82.92 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SURAKSHA.
Suraksha Diagnostic Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹114.31B | 63.11 | ― | 0.20% | 15.79% | 12.14% | |
66 Neutral | ₹234.16B | 68.44 | ― | 0.89% | 10.76% | 26.68% | |
64 Neutral | ₹36.96B | 25.06 | ― | 0.96% | 8.53% | 21.02% | |
62 Neutral | ₹14.69B | 46.67 | ― | ― | ― | ― | |
61 Neutral | ₹99.33B | 60.35 | ― | 0.21% | 18.95% | 9.30% | |
58 Neutral | ₹18.82B | 38.37 | ― | 0.38% | 9.88% | 6.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:SURAKSHA
Suraksha Diagnostic Ltd.
282.05
-16.65
-5.57%
IN:INDRAMEDCO
Indraprastha Medical Corporation Limited
403.15
12.64
3.24%
IN:KRSNAA
Krsnaa Diagnostics Limited
580.10
-130.12
-18.32%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,397.50
26.27
1.92%
IN:METROPOLIS
Metropolis Healthcare Ltd.
479.10
54.34
12.79%
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
1,112.80
116.16
11.66%
Suraksha Diagnostic Ltd. Corporate Events
Suraksha Diagnostic Closes Trading Window Ahead of FY26 Results
Mar 20, 2026
Suraksha Diagnostic Limited has notified the exchanges that it is closing its trading window for designated persons and their immediate relatives from 1 April 2026 until 48 hours after the release of its audited standalone and consolidated financi...
Suraksha Diagnostic CFO K S Ravindra to Step Down by May 31, 2026
Mar 2, 2026
Suraksha Diagnostic Limited has announced that Group Chief Financial Officer and Key Managerial Personnel K S Ravindra has tendered his resignation, which was received by the company on 2 March 2026. His last working day will be on or before 31 Ma...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.